Table 1.
Characteristics of primary spinal cord and appendage tumors in Korea between 2006 and 2010
| Characteristic | Total |
Malignant |
Non-malignant |
|||
|---|---|---|---|---|---|---|
| No. (%) | Ratea) (95% CI) | No. (%) | Ratea) (95% CI) | No. (%) | Ratea) (95% CI) | |
| Total | 3,312 (100) | 1.08 (1.04-1.12) | 443 (100) | 0.16 (0.14-0.18) | 2,869 (100) | 0.92 (0.89-0.96) |
| Age at diagnosis (yr) | ||||||
| 0-9 | 53 (1.6) | 0.20 | 25 (5.6) | 0.10 | 28 (1.0) | 0.11 |
| 10-19 | 125 (3.8) | 0.37 | 32 (7.2) | 0.09 | 93 (3.2) | 0.27 |
| 20-29 | 243 (7.3) | 0.67 | 50 (11.3) | 0.14 | 193 (6.7) | 0.53 |
| 30-39 | 461 (13.9) | 1.08 | 82 (18.5) | 0.19 | 379 (13.2) | 0.89 |
| 40-49 | 721 (21.8) | 1.68 | 78 (17.6) | 0.18 | 643 (22.4) | 1.5 |
| 50-59 | 741 (22.4) | 2.46 | 84 (19.0) | 0.28 | 657 (22.9) | 2.18 |
| 60-69 | 591 (17.8) | 3.03 | 52 (11.7) | 0.27 | 539 (18.8) | 2.76 |
| 70-79 | 314 (9.5) | 2.76 | 26 (5.9) | 0.23 | 288 (10.0) | 2.53 |
| ≥ 80 | 63 (1.9) | 1.59 | 14 (3.2) | 0.35 | 49 (1.7) | 1.24 |
| Gender | ||||||
| Male | 1,477 (44.6) | 0.99 (0.94-1.04) | 265 (59.8) | 0.19 (0.17-0.22) | 1,212 (42.2) | 0.80 (0.75-0.85) |
| Female | 1,835 (55.4) | 1.15 (1.10-1.21) | 178 (40.2) | 0.13 (0.11-0.15) | 1,657 (57.8) | 1.02 (0.97-1.08) |
| Primary site (ICD-O-3 site code) | ||||||
| Spinal meninges (C70.1) | 532 (16.1) | 0.16 (0.15-0.18) | 12 (2.7) | 0.00 (0.00-0.01) | 520 (18.1) | 0.16 (0.15-0.17) |
| Spinal cord (C72.0) | 2,763 (83.4) | 0.91 (0.88- 0.95) | 430 (97.1) | 0.15 (0.14-0.17) | 2,333 (81.3) | 0.76 (0.72-0.79) |
| Cauda equina (C72.1) | 17 (0.5) | 0.01 (0.00-0.01) | 1 (0.2) | 0.00 (0.00-0.00) | 16 (0.6) | 0.01 (0.00-0.01) |
| Histology | ||||||
| Ependymoma | 253 (7.6) | 0.09 (0.07-0.10) | 183 (41.3) | 0.06 (0.05-0.07) | 70 (2.4) | 0.03 (0.02-0.03) |
| Pilocytic astrocytic tumors | 21 (0.6) | 0.01 (0.01-0.02) | 2 (0.5) | 0.00 (0.00-0.00) | 19 (0.7) | 0.01 (0.00-0.01) |
| Other astrocytoma | 59 (1.8) | 0.02 (0.02-0.03) | 52 (11.7) | 0.02 (0.02-0.03) | 7 (0.2) | 0.00 (0.00-0.00) |
| Tumors of the spinal nerves | 1,486 (44.9) | 0.47 (0.45-0.50) | 21 (4.7) | 0.01 (0.00-0.01) | 1,465 (51.1) | 0.47 (0.44-0.49) |
| Neurofibroma, NOS | 69 (2.1) | 0.03 (0.02-0.03) | - | - | 69 (2.4) | 0.03 (0.02-0.03) |
| Neurofibromatosis, NOS | 14 (0.4) | 0.01 (0.00-0.01) | - | - | 14 (0.5) | 0.01 (0.00-0.01) |
| Malignant peripheral nerve sheath tumor | 6 (0.2) | 0.00 (0.00-0.00) | 6 (1.4) | 0.00 (0.00-0.00) | - | - |
| Plexiform neurofibroma | 7 (0.2) | 0.00 (0.00-0.01) | - | - | 7 (0.2) | 0.00 (0.00-0.01) |
| Neurilemoma, NOS | 1,369 (41.3) | 0.43 (0.41-0.45) | - | - | 1,369 (47.7) | 0.43 (0.41-0.45) |
| Neurilemoma malignant | 15 (0.5) | 0.00 (0.00-0.01) | 15 (3.4) | 0.00 (0.00-0.01) | - | - |
| Others | 6 (0.2) | 0.00 (0.00-0.00) | - | - | 6 (0.2) | 0.00 (0.00-0.00) |
| Meningioma | 665 (20.1) | 0.20 (0.19-0.22) | 4 (0.9) | 0.00 (0.00-0.00) | 661 (23.0) | 0.20 (0.19-0.22) |
| Hemangioblastoma | 75 (2.3) | 0.03 (0.02-0.03) | 0 | - | 75 (2.6) | 0.03 (0.02-0.03) |
| Other mesenchymal tumors | 56 (1.7) | 0.02 (0.01-0.02) | 5 (1.1) | 0.00 (0.00-0.01) | 51 (1.8) | 0.02 (0.01-0.02) |
| Lymphomas | 26 (0.8) | 0.01 (0.01-0.01) | 26 (5.9) | 0.01 (0.01-0.01) | - | - |
| Other tumors | 92 (2.8) | 0.04 (0.03-0.05) | 45 (10.2) | 0.02 (0.01-0.03) | 47 (1.6) | 0.02 (0.01-0.03) |
| Unclassified tumors | 579 (17.5) | 0.19 (0.17-0.21) | 105 (23.7) | 0.04 (0.03-0.04) | 474 (16.5) | 0.15 (0.14-0.17) |
| Year of diagnosis | ||||||
| 2006 | 540 (16.3) | 0.92 (0.84-1.00) | 87 (19.6) | 0.16 (0.13-0.20) | 453 (15.8) | 0.76 (0.68-0.83) |
| 2007 | 584 (17.6) | 0.97 (0.89-1.05) | 95 (21.4) | 0.17 (0.13-0.20) | 489 (17.0) | 0.81 (0.73-0.88) |
| 2008 | 679 (20.5) | 1.11 (1.02-1.19) | 89 (20.1) | 0.16 (0.12-0.19) | 590 (20.6) | 0.95 (0.87-1.03) |
| 2009 | 688 (20.8) | 1.10 (1.02-1.19) | 83 (18.7) | 0.15 (0.12-0.19) | 605 (21.1) | 0.95 (0.88-1.03) |
| 2010 | 821 (24.8) | 1.28 (1.19-1.38) | 89 (20.1) | 0.16 (0.12-0.20) | 732 (25.5) | 1.13 (1.04-1.21) |
CI, confidence interval; ICD-O-3, International Classification of Diseases for Oncology, third edition; NOS, not otherwise specified.
a)
Rates are per 100,000 persons and age-adjusted to the world standard population, except age-specific rates, which were not age-adjusted.